IO Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IOBT research report →
Range $0.5 – $0.5
Price Chart
About the company
IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform.
- CEO
- Mai-Britt Zocca
- IPO
- 2021
- Employees
- 80
- HQ
- Copenhagen, DK
Get TickerSpark's AI analysis on IOBT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $885.69K
- P/E
- -0.01
- PEG
- 0.01
- P/S
- 0.00
- P/B
- 0.90
- EV/EBITDA
- 0.50
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -591.35%
- ROIC
- -283.28%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-849,000-12.3%
- Op Income
- $-95,177,000
- Net Income
- $-95,491,000-10.9%
- EPS
- $-1.45+26.8%
- OCF Growth
- -14.8%
- FCF Growth
- -14.3%
- 52W High
- $2.79
- 52W Low
- $0.01
- 50D MA
- $0.27
- 200D MA
- $0.95
- Beta
- 0.89
- RSI (14)
- 23
- Avg Volume
- 19.98M
No earnings-call transcripts are available for IOBT yet.
- Free Float
- 83.9%
- Shares Outstanding
- 71.95M
- Float Shares
- 60.35M
of shares held by institutions
22 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Beacon Pointe Advisors, LLC | 42.60K | ▼ 463.40K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 25 | Smith David V | other | 35,144 |
| Jun 5, 25 | Hunter Heidi | other | 35,144 |
| Jun 5, 25 | Hirth Peter | other | 35,144 |
| Jun 5, 25 | Glaub Kathleen Sereda | other | 35,144 |
| Jun 5, 25 | Elling Christian E | other | 35,144 |
| Jun 5, 25 | Collins Helen Louise | other | 35,144 |
| May 30, 25 | Hunter Heidi | buy | 15,000 |
| Apr 2, 25 | Zocca Mai-Britt | other | 580,000 |
| Apr 2, 25 | Sullivan Amy | other | 215,000 |
| Apr 2, 25 | Smith Devin Whittemore | other | 140,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IOBT coverage
Recent articles, reports, and earnings notes.
No research on IOBT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IOBT report →IO Biotech, Inc. (NASDAQ:IOBT) Receives Consensus Rating of “Reduce” from Analysts
defenseworld.net · Apr 18
Analysts Set IO Biotech, Inc. (NASDAQ:IOBT) PT at $6.33
defenseworld.net · Mar 27
IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decline in Short Interest
defenseworld.net · Mar 2
Here's Why IO Biotech, Inc. (IOBT) Looks Ripe for Bottom Fishing
zacks.com · Feb 13
Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Grows By 47.2%
defenseworld.net · Feb 1
IO Biotech Provides Corporate Update
globenewswire.com · Jan 30
IO Biotech Announces Exploration of Strategic Alternatives
globenewswire.com · Jan 21
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
globenewswire.com · Dec 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.